Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40-75~* Male~* History of chronic kidney disease and cardiorenal syndrome~* Written informed consent~Exclusion Criteria:~* Female~* Acute illness~* Life-threat competitive illness~* Mental disorders~* Endocrinologic diseases (including diabetes mellitus, hyperparathyroidism, and other thyroid disorders)~* Need for dialyses~* Hypercalcemia~* Concomitant use of hormone or cytokine medication~* Participation to any drug-investigation during the previous 60 days as checked with VIP check

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Paricalcitol treatment (Type: ACTIVE_COMPARATOR): 6-8 μg daily per os (orally) without special diet
- Calcitriol treatment (Type: ACTIVE_COMPARATOR): 2-4 μg daily orally under with dietary restrictions of vitamin D
- Cholecalciferol (Type: ACTIVE_COMPARATOR): alendronate sodium/ cholecalciferol capsules with recommended daily allowance equals 1200-2400 IU per day
- Supplemental (Type: OTHER): intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day

Based on this trial design, predict the completion outcome and termination type (if applicable).